HOCl Wound Irrigation System, per-patient bag and single-use head (Aquaceso variant) — desirability

The chair: the user. Here that means the wound nurse at a dressing change in a US hospital, an outpatient wound clinic, a skilled nursing facility or a home health visit. It also means the clinician who writes the wound-care orders, and the patient whose wound is being irrigated.

How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-023.md. The number is the claim's position in its ## Claims list. The tag is copied from that claim as it stands at build time and is never adjusted here. A [no claim] marker means nothing in the file speaks to the condition. Where another lens holds a condition, this deck points at that deck rather than restating it. See docs/deck-spec.md.

What the file looks like from this chair. This deck is built on P1 per-patient HOCl bag, the shape recorded in the loop record as a redesign. P1 per-patient HOCl bag is a per-patient bag of HOCl-preserved saline, opened once and used over a labelled in-use period, plus a fresh single-use head at each session. The nurse squeezes the head to reach the wound-cleansing pressure range. Three things frame what follows.

• No US wound clinician has been asked anything. Whether they believe HOCl cleansing beats saline is recorded as a question and not answered claim 116unconfirmed.
• The label gives the nurse no clinical reason. HOCl is on it as a preservative only, so the reason to pick this up has to be something she can see at the bedside.
• The rubric's nine factors score none of this. The verified claims nearest this chair are guidance, analogies and obstacles. Five of the conditions below rest on assumptions this deck put on record itself (claims 203-207).

Slide 1 — The user, and the moment

Would have to be true: A wound nurse in a US hospital, outpatient wound clinic, skilled nursing facility or home health visit would have to cleanse chronic wounds by pressurised irrigation, rather than by swabbing, soaking or pouring, at most dressing changes. That would have to happen often enough that a single-use head is opened at nearly every session.

Where it stands:

• Guidance points this way. The IWII 2022 consensus says passive soaking or swabbing may not adequately cleanse the wound, and recommends mechanical irrigation at 4-15 psi claim 86verified. Guidance is not practice.
• How often it actually happens is unknown. The share of US wound encounters that use pressurised irrigation has no figure claim 38unconfirmed. Neither does the number of professional irrigations per wound per year claim 36unconfirmed.
• The nearest observations are not US irrigation counts.
  • A Canadian nurse survey found 68% supported gauze soaking but 30% used it routinely. It reports no share of cleansings done by pressurised irrigation claim 108verified. The Verifier's note on that claim records more figures from the full text, including irrigation as the most frequently used cleansing method, and says those figures are not in the claim.
  • Medicare debridement service counts claim 68verified count debridement, not irrigation events.

What would settle it: A US practice survey or utilisation source giving the share of chronic-wound dressing changes that use pressurised irrigation. No connector reaches one, and market returns unverifiable by design. Failing that, the structured clinician calls designed under REQ-0226 Design the primary research that would…, which carry claim 116unconfirmed. Those calls are fieldwork that a human must authorise.

If it's false: If most US dressing changes swab, soak or pour, the head has no moment in the nurse's routine. The per-session cadence that the viability deck's revenue rests on (viability Slide 3) shrinks to the minority of encounters that irrigate. The addressable-share leg of Factor 3 (claim 38unconfirmed) shrinks with it.

Slide 2 — What they'd have to do differently

Would have to be true: At each session the nurse would have to stop drawing saline into a 35 mL syringe or pouring from a bottle. Instead she would spike a fresh head into that patient's opened bag and squeeze its chamber over and over until the session's volume is delivered. She would have to finish the session by hand, without reaching back for the syringe.

Where it stands:

• The hand is the pump. That a nurse can deliver the largest labelled session volume by hand-squeezing, without stopping for fatigue or switching to a syringe, is on record from this deck and unchecked claim 203unverified.
• Why a chamber at all. A hand-compressed IV bag peaked at a median of 4 psi, the bottom of the range claim 143verified. So the head carries its own squeeze chamber. Whether every operator, including at maximal grip, holds the range with it is a study not yet run claim 172unconfirmed.
• How much "a session" is. There is no figure in the file. The feasibility deck's Slide 1 holds that blank claim 210unverified.
• There is no head to hand a nurse claim 63unconfirmed.

What would settle it: A simulated-use session with a panel of wound nurses using a prototype head on a wound model. It would count squeezes per session, time to finish, and every switch back to the syringe. It needs a prototype of defined geometry (feasibility Slide 5).

If it's false: A head that tires the hand gets put down mid-session in favour of the syringe, and in practice the product reverts to the tool it was meant to replace. The way out on the pressure side is a powered head, which is a different device on a different route (feasibility Slide 2).

Slide 3 — Who else has to say yes

Would have to be true: Four parties besides the nurse would each have to agree.

• The clinician who writes the wound-care orders would have to accept the system under existing cleansing orders.
• The infection prevention committee of the facility or agency would have to approve a bag that a new head re-enters at every session.
• Staff in every setting would have to keep each opened bag with its own patient and discard it on time.
• The value-analysis committee would have to put on formulary a head that fits only its own maker's bag. That last condition is held in the viability deck.

Where it stands:

• Orders. That wound-care physicians and nurse practitioners accept the system under their existing cleansing orders or protocols, without a product-specific order, is on record from this deck claim 207unverified.
• Infection prevention. That committees approve a multiple-use, single-patient HOCl bag re-entered by a new head each session is on record from this deck claim 206unverified. The configuration is not new: the one cleared HOCl irrigation bag is labelled for multiple use within a single patient claim 122verified. What no claim covers is a committee's view of a bag re-spiked at every dressing change.
• Custody of the opened bag. That staff keep it assigned to one patient and discard it at the end of its in-use period, with no bag used on a second patient, is on record from this deck claim 205unverified. Who holds an opened bag between outpatient visits is not said in intended_use: or mechanism:. The loop handed that question to the owner as REQ-0235 For the P1 per-patient HOCl bag.
• Formulary for a keyed head claim 162unconfirmed. Stated in full in the viability deck, Slide 6.
• The only home-setting preference in the file is Danish, not American. It assumes Danish home-care nurses would value a self-contained, shielded kit claim 27unconfirmed.

What would settle it: Structured interviews with wound physicians and nurse practitioners, and with infection prevention leads in each of the four settings. A review of a few sites' written policies on multiple-use single-patient wound products would also bear on it. Both are human-run, and no connector reaches either.

If it's false: One refusal stops use at that site. An infection prevention refusal does the most damage, because it removes the bag, and P1 per-patient HOCl bag has no other label for its preserved bag. FDA (US Food and Drug Administration)'s 2023 proposal accepts a preservative only in a nonsterile wash or a multiple-use single-patient wash claim 119verified. That collapse is spelled out as the feasibility deck's load-bearing condition.

Slide 4 — What it costs them

Would have to be true:

• Time. Per session, the nurse would have to spend less hands-on time on set-up, irrigation and splash clean-up than with saline and a syringe.
• Comfort. The patient would have to accept irrigant at room temperature.
• No gear saved. The nurse would still wear her face and eye protection, so the product would have to earn its place without displacing any of it.

Where it stands:

• Time. That a session with the head and bag takes less hands-on time than a syringe with a 19G angiocatheter is on record from this deck claim 204unverified. The buyer claim names reduced set-up time, PPE use and clean-up as its premise, and nobody has measured them claim 161unconfirmed. Splash reduction for this design is unquantified claim 49unconfirmed claim 173unconfirmed.
• Protective equipment. OSHA requires masks with eye protection or chin-length face shields wherever splash can be anticipated claim 48verified. The business case assumes an integral shield does not lift that duty claim 197unverified. The money side of this is held in the viability deck, Slide 3. For the nurse, the shield adds protection; it takes no gear away.
• Temperature. P1 per-patient HOCl bag does not warm its irrigant, which the referred Aquaceso system is said to do claim 1unconfirmed. Two randomized trials found that patients preferred warmed saline, or that it reduced pain and anxiety, with no difference in wound outcomes where outcomes were measured claim 175verified. That is a verified cost to the patient.
• Money out of pocket. The nurse pays nothing. A patient would pay only if a bag went home outside home health. Wound cleansers (A6260 (a HCPCS code for a supply)) are non-covered under the Part B surgical dressing benefit claim 29verified, and whether any other Part B benefit pays is not established claim 166unconfirmed.

What would settle it: A time-and-motion comparison against a 35 mL syringe in simulated use, run alongside the Slide 2 session. A comfort item in any later clinical-use study.

If it's false: If no time is saved and the patient is less comfortable, the nurse gets a slower, colder session and no visible gain. The buyer premium in claim 161unconfirmed then loses the premise it names.

Slide 5 — What would make them believe it

Would have to be true: The label cannot say that HOCl does anything in the wound. So a US wound clinician would have to choose the system for one of two reasons. Either she can see the benefit (less spray on her face and chest from the shield, with no chlorine in the air she breathes), or she already believes that HOCl cleansing beats saline.

Where it stands:

• What the label cannot carry. Reading a wound-antimicrobial claim as a drug claim is reasoning, unconfirmed claim 10unconfirmed. FDA's proposal says a use to "deliver antimicrobials to the wound" may not fall under CDRH (Center for Devices and Radiological Health)'s jurisdiction claim 121verified.
• Belief. Whether US clinicians believe HOCl beats saline is unanswered claim 116unconfirmed. The trials do not supply a reason:
  • a 2022 systematic review found no eligible study of chlorous agents in chronic wounds claim 93verified;
  • no RCT (randomised controlled trial) of 100 or more patients showing a healing benefit was found claim 141unconfirmed;
  • Urgo's randomized trial of Vashe against saline is not yet recruiting claim 142verified.
• Revealed behaviour. One US burn centre used HOCl as the initial antiseptic in 11.3% of grafted patients claim 107verified. IWII's withdrawal of traditional hypochlorite from open wounds does not cover HOCl-preserved solutions claim 87verified.
• The visible result.
  • A shielded syringe significantly cut splatter on the irrigator's face and chest in a 1993 beef-wound model claim 101verified. For this head, driven by its chamber, the same comparison has not been run claim 173unconfirmed.
  • Breathing-zone chlorine with the head is untested claim 191unconfirmed.
  • The aerosol evidence is analogy only: HOCl fog was cytotoxic to cultured cells at 500 ppm and not at 300 ppm claim 99verified, and sprayed hypochlorite left chlorine below detection in surface disinfection claim 100verified.

What would settle it: The simulated-use splatter and breathing-zone chlorine tests in claims 173 and 191, which are bench work on a prototype. The desk search filed as a research row on US clinician HOCl belief. Then the clinician calls under REQ-0226 Design the primary research that would….

If it's false: The nurse has no reason she can name, and the product sells on convenience alone. The premium the viability deck needs then rests entirely on the time saving in Slide 4.

Slide 6 — The cheapest way to find out

Would have to be true: In a first handful of structured calls and one simulated-use session, US wound nurses would have to do three things:

• report that they irrigate at pressure at most dressing changes;
• with a mock head in hand, finish a session's volume by squeezing, faster than with a syringe;
• name what, if anything, would stop their unit adopting a bag reused across sessions.

Where it stands: None of this has been observed. The questions are on record as claim 116unconfirmed, claim 38unconfirmed, claim 203unverified, claim 204unverified and claim 206unverified. The REQ-0226 Design the primary research that would… instrument exists as a design. Fielding it is the owner's decision.

What would settle it: The calls, which are human-run and need the owner's authorisation, and the simulated-use session, which needs a prototype or a printed mock head.

If it's false: Any of three observations in a small sample would show Slides 1-3 failing, at the cost of the calls:

• nurses report swabbing or pouring as their routine;
• nurses pick the syringe back up mid-session;
• infection prevention leads refuse a reused bag.

Slide 7 — Where this deck outruns the file

Every condition above with nothing verified behind it that supports it. The verified claims on this deck are guidance (claim 86verified), an analog at syringe pressure (claim 101verified), and obstacles (claims 119, 175, 29). None of them is backing for a condition.

• Nurses irrigate at pressure at most dressing changes (Slide 1) — claim 38unconfirmed claim 36unconfirmed. Settled by a US practice survey or the clinician calls (REQ-0226 Design the primary research that would…), human-run.
• A full session can be squeezed by hand without fatigue or a switch to the syringe (Slide 2) — claim 203unverified claim 172unconfirmed. Newly on record from this deck. Settled by a simulated-use session on a prototype.
• Ordering clinicians accept it under existing orders (Slide 3) — claim 207unverified. Newly on record. Settled by interviews.
• Infection prevention approves a re-spiked single-patient bag (Slide 3) — claim 206unverified. Newly on record. Settled by interviews and a policy review.
• Staff keep each opened bag with its patient and discard it on time (Slide 3) — claim 205unverified. Newly on record. Depends on the owner's custody decision (REQ-0235 For the P1 per-patient HOCl bag). Settled by observation in a pilot setting.
• Buyers accept a keyed head on formulary (Slide 3, held in viability) — claim 162unconfirmed.
• Less hands-on time per session than a syringe (Slide 4) — claim 204unverified claim 161unconfirmed. Newly on record. Settled by a time-and-motion study.
• Measurably less splatter and no chlorine in the breathing zone (Slide 5) — claim 173unconfirmed claim 191unconfirmed. Settled by bench simulated use.
• Clinicians believe HOCl beats saline (Slide 5) — claim 116unconfirmed. Settled only by primary research.

Every condition on this deck is on that list, so all six conditions have nothing verified behind them. The one verified claim that bears on a condition at all is an analog: the 1993 shield study was at syringe pressure with a different shield (claim 101verified).

Slide 8 — The load-bearing condition

If only one thing from this chair could be checked: whether a US wound nurse, handed the P1 per-patient HOCl bag head in place of the syringe she uses now, would see a per-session advantage she can name without a clinical claim on the label: less hands-on time, or measurably less spray on her face and chest with no chlorine in her breathing zone claim 204unverified claim 173unconfirmed.

Why this one rather than the others:

• The label rules out the clinical reason, and the trial evidence does not supply one (claims 93, 141). So everything this chair would want from the product has to be visible at the bedside.
• Slides 1 and 3 ask whether the moment exists and who must consent. This one asks whether, given the moment, the nurse picks the head up. If she would not, consent and frequency do not matter.
• It is checkable in simulated use, on a mock head, before any bag exists.

Naming it is not a recommendation, a gate, or a kill. It is the answer to "check what first."